

**PRODUCT INFORMATION**

|   |   |
|---|---|
| <b>Common Name</b>                      | LY-2439821;LY2439821;LY 2439821;Taltz   |
| <b>Conjugate</b>                        | Biotinylated  |
| <b>Synonyms</b>                         | IL17;CTLA8;IL-17;ILA17;CTLA-8;IL-17A  |
| <b>Applications</b>                     | N/A   |
| <b>Endotoxin</b>                        | Less than 1.0 EU/μg by the LAL method. For <1 EU/mg requirements, please contact us for customization.  |
| <b>Recommended Dilutions</b>            | N/A   |
| <b>Formulation &amp; Reconstitution</b> | Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.   |
| <b>Host Species</b>                     | N/A   |
| <b>IgG type</b>                         | IgG4  |
| <b>Reactivity</b>                       | Human   |
| <b>Target</b>                           | IL17A   |
| <b>Uniprot ID</b>                       | Q16552  |
| <b>Description</b>                      | Biotinylated Anti-IL17A(ixekizumab biosimilar) mAb  |
| <b>Delivery</b>                         | 6-8 weeks   |
| <b>Storage&amp;Shipping</b>             | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
| <b>Sterility</b>                        | Products are supplied non-sterile. For cell culture applications, dilute in appropriate medium and sterile-filter (0.22 μm) prior to use.   |
| <b>Background</b>                       | Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.   |
| <b>Usage</b>                            | Research use only   |

